NCT05945823 2026-04-09
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT06506955 2026-04-03
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Taiho Oncology, Inc.
Phase 2/3 Enrolling by invitation
NCT04507503 2026-03-10
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Taiho Oncology, Inc.
Approved for marketing
NCT05827614 2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1 Active not recruiting
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT05727176 2025-12-29
FOENIX-CCA4
Taiho Oncology, Inc.
Phase 2 Recruiting
NCT04024436 2025-11-13
A Study of TAS-120 in Patients With Metastatic Breast Cancer
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04189445 2025-10-08
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
Phase 2 Terminated
NCT02052778 2025-03-27
A Study of TAS-120 in Patients With Advanced Solid Tumors
Taiho Oncology, Inc.
Phase 1/2 Completed
NCT04999761 2024-09-25
AB122 Platform Study
Taiho Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT04965818 2024-09-19
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Taiho Oncology, Inc.
Phase 1 Terminated